Sunshine Biopharma (SBFMW) Receivables (2015 - 2026)

Sunshine Biopharma has reported Receivables for 11 years, with the latest figure at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 16.44% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 16.44% YoY), and the FY2025 full-year result was $3.5 million, down 10.56% from the prior year.
• Receivables for Q1 2026 stood at $4.0 million, up from $3.5 million in the prior quarter.
• The five-year high for Receivables was $4.2 million in Q3 2025, with the low at $22.0 in Q3 2022.
• Historically, Receivables has averaged $2.5 million across 5 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables sank 98.05% — and 2023, when it jumped 9245895.45%.
• Sunshine Biopharma's Receivables stood at $1.9 million in 2022, then jumped by 33.48% to $2.6 million in 2023, then soared by 51.56% to $3.9 million in 2024, then declined by 10.56% to $3.5 million in 2025, then increased by 15.95% to $4.0 million in 2026.
• The last three Receivables figures came in at $4.0 million (Q1 2026), $3.5 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.